Can serum surfactant protein d or cc-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1114-1120

  Elhaj, Mona ^a   Charles, Julio ^a   Pedroza, Claudia ^a   Liu, Xiaochun ^a   Zhou, Xiaodong ^a   Estrada Y Martin, Rosa M ^a   Gonzalez, Emilio B ^b   Lewis, Dorothy E ^a   Draeger, Hilda T ^c   Kim, Sarah ^a   Arnett, Frank C ^a   Mayes, Maureen D ^a   Assassi, Shervin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cc Chemokine Ligand 18; Interstitial Lung Disease; Surfactant D; Systemic Sclerosis

Indexed keywords

BETA CHEMOKINE; CC CHEMOKINE LIGAND 18; IMMUNOSUPPRESSIVE AGENT; LIGAND; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CC CHEMOKINE LIGAND 18 BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM; SURFACTANT PROTEIN D BLOOD LEVEL; SURVIVAL; SYSTEMIC SCLEROSIS;

CC-CHEMOKINE LIGAND 18; INTERSTITIAL LUNG DISEASE; SURFACTANT D; SYSTEMIC SCLEROSIS;

ADULT; AGED; CHEMOKINES, CC; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; VITAL CAPACITY;

EID: 84879981373     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120997     Document Type: Article

References (21)

1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatology 2012;51:1017-26.
2. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: A 20 year followup study. J Rheumatol 2003;30:958-65.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
4. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
5. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YMR, Draeger HT, et al. Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
6. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
7. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis-continuing progress in developing clinical measures of response. J Rheumatol 2007;34:1194-200.
8. Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011;63:3078-85.
9. Wright Jr. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005;5:58-68.
10. Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009;36:773-80.
11. Asano Y, Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001;44:1363-9.
12. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004;31:1112-20.
13. Bonella F, Volpe A, Caramaschi P, Nava C, Ferrari P, Schenk K, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: Correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011;28:27-33.
14. Schutyser E, Richmond A, Van DJ. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 2005;78:14-26.
15. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: A sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005;52:2889-96.
16. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007;56:1685-93.
17. Tiev KP, Hua-Huy T, Kettaneh A, Gain M, Duong-Quy S, Toledano C, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011;38:1355-60.
18. Sweeting MJ, Thompson SG. Joint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and rupture. Biom J 2011;53:750-63.
19. Rizopoulos D. JM: An R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw 2010;35:1-33.
20. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490-8.
21. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.